BPC-157 in Q3 2026: the FDA panel vote

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A bulks list, the register of substances that state-licensed compounding pharmacies may lawfully prepare^[1]. The committee reached that result after the FDA's own reviewers had recommended against it^[1]. Nothing in the human evidence base moved between the staff review and the vote. What moved was the panel's view of who should be making the call.

What the panel voted on, and against

The meeting ran across 23 and 24 July and covered seven peptides, each in free base and acetate form. BPC-157, KPV, TB-500 and MOTs-c came up on the first day; Emideltide, Epitalon and Semax on the second^[2]. Six of the seven were recommended for inclusion. Emideltide was the only one voted down, 6 to 7 with one abstention. BPC-157, KPV and TB-500 each cleared by the same 8 to 6 margin with one abstention^[2].

The FDA had gone into the meeting recommending against BPC-157 in both salt forms, citing safety and efficacy concerns, and the briefing package pointed to a lack of evidence supporting effectiveness in ulcerative colitis, the indication under review^[1]. The members who voted no said much the same thing out loud. Elizabeth Rebello of the University of Texas MD Anderson Cancer Center pointed to the lack of efficacy data and randomised controlled trials. Bill Zamboni put it more bluntly: "There are too many unknowns about this product."^[1]

The majority did not claim the evidence was stronger than that. They argued the decision sat with someone else. David Pope of XiFin Pharmacy Solutions gave the clearest version of the reasoning:

I voted yes because it's time to put this decision back in the hands of the physician and pharmacist.

What the vote does not do

It does not make BPC-157 an approved medicine anywhere. PCAC recommendations are advisory. Before any substance actually joins the 503A bulks list, the FDA has to run formal notice-and-comment rulemaking, and commentary on the meeting expects that to land in 2027 at the earliest, possibly later^[2]. Until it completes, no compounding pharmacy has unambiguous legal authority to prepare BPC-157 for a patient.

The second distinction matters more. The 503A bulks list governs what a pharmacy may compound against an individual prescription. It is not a marketing authorisation, and it does not involve the new-drug review that establishes efficacy and a defensible adverse-event profile. Outside the US the vote changes nothing at all: BPC-157 has no authorisation from the EMA, the MHRA, or any national agency, and the per-country picture on this site is unchanged. That includes the UK and Germany, where the compounding route the PCAC was debating has no equivalent. Readers in the US should read the vote alongside the United States regulation page rather than in place of it.

The evidence that arrived this quarter

A narrative review published in Pharmaceutics on 20 May 2026 by Mateescu and colleagues put a number on the human evidence base that is worth sitting with. Available clinical data, the authors write, "derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations"^[3]. They add that "no pharmaceutical-grade formulation has been developed or validated," and that the peptide still lacks permeability characterisation and formal excipient compatibility work^[3]. The same review notes the odd pharmacology that keeps the compound interesting: unusual stability in gastric juice, activity reported by oral, parenteral and topical routes, and a plasma half-life under 30 minutes despite biological effects that persist for hours to days^[3].

The other publication worth flagging appeared in the Journal of Clinical Medicine on 2 May 2026. Yildirim and colleagues took residual internal mammary artery segments from twelve coronary bypass patients and tested BPC 157 on the dissected rings. The finding: "BPC 157 induced concentration-dependent vasorelaxation in human arterial tissue, predominantly mediated via an endothelium-dependent NO pathway"^[4]. The authors describe this as early mechanistic evidence and state that "further molecular and in vivo studies are required to clarify its clinical relevance"^[4]. Human tissue, not human patients. That is a real step past the rodent work that dominates the BPC-157 mechanism section, and it is still a long way from a clinical outcome.

The trial worth watching

One controlled human trial is now recruiting. NCT07437547, sponsored by Hudson Biotech, is a randomised, double-blind, placebo-controlled Phase 2 study in acute grade II hamstring strain confirmed by MRI, with quadruple masking and an estimated enrolment of 120 participants^[5]. Both arms follow the same standardised rehabilitation programme; the trial administers once-daily subcutaneous BPC 157 or matching placebo for 14 days. The co-primary endpoints are time to return to unrestricted sport and change from baseline to Day 14 in MRI-assessed injury volume, read by blinded central radiology^[5].

Two honest caveats. This trial was first posted on 27 February 2026, so it is not a Q3 development, and we are including it because the PCAC vote made it more relevant, not because it is new. And it is running at a single site, Peking University Shenzhen Hospital, with primary completion estimated for February 2027^[5]. A single-site Phase 2 with 120 participants will not settle the question. It would still be the first controlled readout of any size, which is more than the compounding debate currently has to work with.

Where this leaves a reader

If the rulemaking eventually follows the committee, the practical change for a US reader is the supply chain rather than the science. A 503A pharmacy operates under identity, potency and sterility requirements that a research-chemical vendor does not, so the vial contents become more predictable. That is a harm-reduction improvement, and it is not an efficacy finding. Everything in the safety and unknowns sections of our BPC-157 page still stands: no completed randomised trial reports a defensible adverse-event profile in people, and long-term use is uncharacterised. The same holds for TB-500, which cleared the panel on the identical margin with an evidence base of comparable thinness.

For everyone else, the quarter's headline is a procedural one. A divided advisory panel decided that prescribers and pharmacists should hold this call, over the objection of the agency's own reviewers and several of its own members. That is a governance answer, not a scientific one, and the scientific gap the FDA staff described is exactly as wide on 2 August as it was in April. If you are weighing BPC-157, the conversation belongs with a clinician who knows your history, and the next date that matters is whether the FDA opens rulemaking at all.